Kforce Beats Up on Analysts Yet Again

Kforce (Nasdaq: KFRC  ) reported earnings on Feb. 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Kforce beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded, and GAAP earnings per share expanded significantly.
Gross margins contracted, operating margins shrank, and net margins were steady.
Revenue details
Kforce reported revenue of $285.6 million. The eight analysts polled by S&P Capital IQ expected revenue of $281.7 million. Sales were 10% higher than the prior-year quarter's $258.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
EPS came in at $0.20. The eight earnings estimates compiled by S&P Capital IQ averaged $0.19 per share. GAAP EPS of $0.20 for Q4 were 25% higher than the prior-year quarter's $0.16 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 31.2%, 70 basis points worse than the prior-year quarter. Operating margin was 4.1%, 20 basis points worse than the prior-year quarter. Net margin was 2.5%, about the same as the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $285.3 million. On the bottom line, the average EPS estimate is $0.15.
Next year's average estimate for revenue is $1.19 billion. The average EPS estimate is $0.86.
Investor sen! timentThe stock has a five-star rating (out of five) at Motley Fool CAPS, with 87 members rating the stock outperform and 10 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Kforce a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Kforce is outperform, with an average price target of $15.38.
Over the decades, small-cap stocks, like Kforce have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.

• Add Kforce to My Watchlist.

Nektar Therapeutics Positive Trend - NASDAQ:NKTR

Nektar Therapeutics (NASDAQ:NKTR) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Nektar Therapeutics witnessed volume of 4.38 million shares during last trade however it holds an average trading capacity of 1.24 million shares. NKTR last trade opened at $6.17 reached intraday low of $6.15 and went +6.84% up to close at $6.72.
NKTR has intra-day market capitalization $768.94 million and an enterprise value at $732.66 million. Trailing twelve months price to sales ratio of the stock was 7.13 while price to book ratio in most recent quarter was 3.12. In profitability ratios, net profit margin in past twelve months appeared at -117.87% whereas operating profit margin for the same period at -96.46%.
The company made a return on asset of -10.59% in past twelve months and return on equity of 0.94% for similar period. In the period of trailing 12 months it generated revenue amounted to $101.01 million gaining $0.94 revenue per share. Its year over year, quarterly growth of revenue was -28.60%.
According to preceding quarter balance sheet results, the company had $266.49 million cash in hand making cash per share at 2.33. The total of $230.21 million debt was there putting a total debt to equity ratio 99.74. Moreover its current ratio according to same quarter results was 1.07 and book value per share was 2.02.
Looking at the trading information, the stock price history displayed that its S&P500 52 Week Change illustrated -0.46% where the stock current price exhibited up beat from its 50 day moving average price of $5.40 and remained above from its 200 Day Moving Average price of $5.51.
NKTR holds 114.43 million outstanding shares with 95.49 million floating shares where insider possessed 6.87% and institutions kept 90.20%.